Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The expanding proteome of the molecular chaperone HSP90.

Samant RS, Clarke PA, Workman P.

Cell Cycle. 2012 Apr 1;11(7):1301-8. doi: 10.4161/cc.19722. Epub 2012 Apr 1.

2.

Dynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapy.

Fierro-Monti I, Echeverria P, Racle J, Hernandez C, Picard D, Quadroni M.

PLoS One. 2013 Nov 27;8(11):e80425. doi: 10.1371/journal.pone.0080425. eCollection 2013.

3.

The therapeutic target Hsp90 and cancer hallmarks.

Miyata Y, Nakamoto H, Neckers L.

Curr Pharm Des. 2013;19(3):347-65. Review.

PMID:
22920906
4.

Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.

Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R.

Cancer Treat Rev. 2013 Jun;39(4):375-87. doi: 10.1016/j.ctrv.2012.10.001. Epub 2012 Nov 28. Review.

PMID:
23199899
5.

E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells.

Samant RS, Clarke PA, Workman P.

Proc Natl Acad Sci U S A. 2014 May 6;111(18):6834-9. doi: 10.1073/pnas.1322412111. Epub 2014 Apr 23.

6.

Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.

Alarcon SV, Mollapour M, Lee MJ, Tsutsumi S, Lee S, Kim YS, Prince T, Apolo AB, Giaccone G, Xu W, Neckers LM, Trepel JB.

Curr Mol Med. 2012 Nov 1;12(9):1125-41. Review.

7.

HSP90 and its inhibitors.

Hao H, Naomoto Y, Bao X, Watanabe N, Sakurama K, Noma K, Motoki T, Tomono Y, Fukazawa T, Shirakawa Y, Yamatsuji T, Matsuoka J, Takaoka M.

Oncol Rep. 2010 Jun;23(6):1483-92. Review.

PMID:
20428801
8.

Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).

Solárová Z, Mojžiš J, Solár P.

Int J Oncol. 2015 Mar;46(3):907-26. doi: 10.3892/ijo.2014.2791. Epub 2014 Dec 10. Review.

PMID:
25501619
9.

Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.

Soga S, Akinaga S, Shiotsu Y.

Curr Pharm Des. 2013;19(3):366-76. Review.

PMID:
22920907
10.

Hsp90 molecular chaperone inhibitors: are we there yet?

Neckers L, Workman P.

Clin Cancer Res. 2012 Jan 1;18(1):64-76. doi: 10.1158/1078-0432.CCR-11-1000. Review.

11.

Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Stravopodis DJ, Margaritis LH, Voutsinas GE.

Curr Med Chem. 2007;14(29):3122-38. Review.

PMID:
18220746
12.
13.

Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.

Messaoudi S, Peyrat JF, Brion JD, Alami M.

Expert Opin Ther Pat. 2011 Oct;21(10):1501-42. doi: 10.1517/13543776.2011.594041. Epub 2011 Jun 21. Review.

PMID:
21689065
14.

Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.

Garg G, Khandelwal A, Blagg BS.

Adv Cancer Res. 2016;129:51-88. doi: 10.1016/bs.acr.2015.12.001. Epub 2016 Feb 10. Review.

PMID:
26916001
15.

Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.

Tsutsumi S, Neckers L.

Cancer Sci. 2007 Oct;98(10):1536-9. Epub 2007 Jul 23. Review.

16.

Maximizing the Therapeutic Potential of HSP90 Inhibitors.

Butler LM, Ferraldeschi R, Armstrong HK, Centenera MM, Workman P.

Mol Cancer Res. 2015 Nov;13(11):1445-51. doi: 10.1158/1541-7786.MCR-15-0234. Epub 2015 Jul 28. Review.

17.

Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.

Woodford MR, Dunn D, Miller JB, Jamal S, Neckers L, Mollapour M.

Adv Cancer Res. 2016;129:31-50. doi: 10.1016/bs.acr.2015.09.002. Epub 2015 Oct 23. Review.

PMID:
26916000
18.

Heat shock protein 90: the cancer chaperone.

Neckers L.

J Biosci. 2007 Apr;32(3):517-30. Review.

19.

Alternative approaches to Hsp90 modulation for the treatment of cancer.

Hall JA, Forsberg LK, Blagg BS.

Future Med Chem. 2014 Sep;6(14):1587-605. doi: 10.4155/fmc.14.89.

20.

Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?

Isaacs JS.

Expert Opin Investig Drugs. 2005 Jun;14(6):569-89. Review.

PMID:
16004589

Supplemental Content

Support Center